CD274 and diabetes mellitus: However, whether this risk arises from the immunomodulatory effects of PD-L1 blockade itself or from confounding factors such as diabetes or prior immunosuppressive therapy remains uncertain (Ahmed et al., 2022; Franco et al., 2024).